Summary
We have released the latest research "The Future of Metabolic Disorder Therapeutics-
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
Scope
The scope of this report includes:
* Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015
* Analysis of the leading therapeutic segments including diabetes and obesity.
* Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
* Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
* Key drivers and barriers that have a significant impact on the market
* Coverage of pipeline molecules in various phases of drug development
* Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.
* Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
* Align product portfolio to the markets with high growth potential
* Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
* Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
* Develop key strategic initiatives by understanding key focus areas of leading companies
* Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
Table of Contents
1 Executive Summary
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Report Guidance
4 Global Metabolic Disorder Therapeutics Market: Market Overview
4.1 Introduction
4.2 Revenue Forecasts for the Global Metabolic Disorder Therapeutics Market
4.2.1 Sales Value
4.2.2 Sales Volume
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Usage Patterns
4.2.5 Geographical Segmentation
4.2.6 Generics' Share in the Global Metabolic Disorders Market
4.3 SWOT Analysis
4.3.1 Strength
4.3.2 Weakness
4.3.3 Opportunity
4.3.4 Threat
4.4 Metabolic Disorder Therapeutics Market Drivers
4.4.1 Steady Growth in the Ageing Population
4.4.2 Improvements in the Diagnosis of the Disease
4.4.3 Launch of New Treatments with More Innovative Medicines in Pipeline
4.4.4 Increase in the Incidence of Lifestyle Diseases such as Obesity and Diabetes
4.5 Metabolic Disorder Therapeutics Market Restraints
4.5.1 Patent Expirations
4.5.2 Concerns over Drug Safety
4.5.3 Tightened Reimbursement pressures causing problems in the global Metabolic Disorder Therapeutics market growth
5 Global Metabolic Disorder Therapeutics Market: Geographical Distribution of Revenues
5.1 Geographic Break-up
5.2 The US
5.2.1 Sales Value
5.2.2 Sales Volume
5.2.3 Annual Cost of Therapy
5.2.4 Treatment Usage Patterns
5.3 Top Five Countries in Europe
5.3.1 Sales Value
5.3.2 Sales Volume
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Usage Patterns
5.4 Japan
5.4.1 Sales Value
5.4.2 Sales Volume
5.4.3 Annual Cost of Therapy
5.4.4 Treatment Usage Patterns
6 Global Metabolic Disorder Therapeutics Market:
6.1 Diabetes Market
6.1.1 Introduction
6.1.2 Unmet Needs
6.1.3 Sales Value
6.1.4 Sales Volume
6.1.5 Annual Cost of Therapy
6.1.6 Treatment Usage Patterns
6.1.7 Geographical Segmentation
6.1.8 Generics' Share in the Global Diabetes Market
6.1.9 Drivers
6.1.10 Inhibitors
6.2 Obesity Market
6.2.1 Introduction
6.2.2 Sales Value
6.2.3 Sales Volume
6.2.4 Annual Cost of Therapy
6.2.5 Treatment Usage Patterns
6.2.6 Geographical Segmentation
6.2.7 Generics' Share in the Global Obesity Market
6.2.8 Drivers of Obesity Market
6.2.9 Restraints of Obesity Market
7 Global Metabolic Disorder Therapeutics Market: Pipeline Analysis
7.1 Introduction
7.1.1 Obesity
7.1.2 R&D Strategies
7.2 R&D Trends
7.2.1 New Promising Treatments for Diabetic Retinopathy
7.2.2 Identifying Biomarkers
7.2.3 Combination Drugs
7.2.4 First-in-class Insulin Pills (oral delivery) in Development
7.3 New Drug Insulin Delivery Systems
7.3.1 Altea Therapeutics Transdermal Passport? System
7.3.2 Technosphere®/
7.4 Profiles of Key Novel Late-Stage Drugs
7.5 Major Marketed Drugs under Late-Stage Pipeline
7.5.1 Eisai's Actos
7.5.2 Amgen's Aranesp
7.5.3 Eli Lilly's Byetta
8 Global Metabolic Disorders Therapeutics Market: Competitive Landscape
8.1 Diabetes Market Overview
8.2 Market Share Analysis: Diabetes Therapeutics
8.3 Obesity Market Overview
8.4 Market Share Analysis: Obesity Therapeutics
8.5 Competitive Profiling
8.5.1 Novo Nordisk
8.5.2 Sanofi-aventis
8.5.3 Takeda
8.5.4 Eli Lilly
8.5.5 GlaxoSmithKline (GSK)
8.5.6 Merck & Co Inc.
8.5.7 Amylin Pharmaceuticals
8.5.8 Roche
8.5.9 Abbott
9 Global Metabolic Disorders Therapeutics Market: M&A Landscape
9.1 Overview
9.1.1 Ligand Pharmaceuticals acquired Metabasis Therapeutics in October 2009
9.1.2 CombinatoRx, Inc. Acquired Neuromed Pharmaceuticals, Inc. in August 2009
9.1.3 Mylan Laboratories Acquired Matrix Laboratories Limited in March 2009
9.1.4 Pfizer Acquired Wyeth in January 2009
9.1.5 Wyeth Acquired Thiakis Ltd. in December 2008
9.1.6 Bellus Health Inc. Acquired Innodia Inc in July 2008
9.1.7 GlaxoSmithKline Acquired Sirtris Pharmaceuticals in April 2008
9.1.8 Point Therapeutics and Dara Biosciences Merged in February 2008
9.1.9 Teva Pharmaceutical Industries Acquired Cogenesys, Inc. in January 2008
9.2 R&D Licensing Agreements
9.2.1 Deals by Indication
9.2.2 Deals by Phase
9.2.3 Deals by Geography
9.2.4 Deals by Licensing Type
9.2.5 Deals by Value ($)
9.2.6 Preclinical
9.2.7 Phase I
9.2.8 Phase II
9.2.9 Phase III
9.2.10 Approved
10 Appendix
10.1 Market Definitions
10.2 Key Support Data
10.3 Abbreviations
10.4 Research Methodology
10.4.1 Epidemiology-
10.5 Related Reports
10.6 Contact Us
10.7 Disclaimer
10.8 Sources
1.1 List of Tables
Table 1: Metabolic Disorders Market, Global, Sales Value ($ bn), 2000-2008
Table 2: Metabolic Disorders Market, Global, Sales Value ($ bn), 2008-2015
